<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052999</url>
  </required_header>
  <id_info>
    <org_study_id>TRPV1-ROSACEA_IIT</org_study_id>
    <nct_id>NCT02052999</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients</brief_title>
  <official_title>An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of
      Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Investigator Global Assessment (IGA)</measure>
    <time_frame>Baseline through Study Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>-</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema severity</measure>
    <time_frame>Baseline through Study Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telangiectasia severity</measure>
    <time_frame>Baseline through Study Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory lesion counts</measure>
    <time_frame>Baseline through Study Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>-</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Erythematotelangiectatic Rosacea</condition>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>PAC-14028 cream 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 1%, twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rozex gel 0.75%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rozex gel 0.75%, twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle, twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 1%</intervention_name>
    <description>Participants received topical PAC-14028 cream 1% twice daily for 8 weeks</description>
    <arm_group_label>PAC-14028 cream 1%</arm_group_label>
    <other_name>PAC-14028</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Participants received topical Vehicle twice daily for 8 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Vehicle of PAC-14028 Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rozex gel 0.75%</intervention_name>
    <description>Participants received topical Rozex gel 0.75% twice daily for 8 weeks</description>
    <arm_group_label>Rozex gel 0.75%</arm_group_label>
    <other_name>Rozex gel 0.75%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients at the age of 20 to 65 years old

          -  Clinical diagnosis of erythematotelangiectatic or papulopustular rosacea according to
             National Rosacea Committee Expert Society with

               -  Erythema severity ≥ 1

               -  Telangiectasia severity ≥ 1

               -  At least 3 papules or pustules in facial region

          -  IGA score ≥ 2

          -  Voluntarily signed written informed consent forms for study participation

        Exclusion Criteria:

          -  Patients who are unable to be diagnosed or evaluated for rosacea due to tattoo or
             scar in the facial area

          -  Patients who are unable to be diagnosed or evaluated for rosacea due to excess
             hair(e.g., mustache, beard, whiskers etc.) in the facial area

          -  Patients who are sensitive to the drug or vehicle

          -  Previous administration of oral retinoid or vitamin A(≥10,000 units/day) within 6
             months prior to visit 1

          -  Previous use of estrogen or oral contraceptives within 3 months prior to visit 1

          -  Previous use of topical retinoids or oral antibiotics (e.g., tetracycline,
             tetracycline derivatives, erythromycin, erythromycin derivatives, sulfamethoxazole,
             trimethoprim) or oral steroid for the treatment of facial rosacea within 1 month
             prior to visit 1

          -  Previous use of topical steroid or topical antibiotics, topical treatment for
             rosacea(e.g., metronidazole, azelaic acid) within 2 weeks prior to visit 1

          -  Presently undergoing anti-coagulant therapies

          -  History of hematologic disease

          -  Ocular-only, Phymatous rosacea, or papulopustular rosacea patients who require
             systemic antibiotics

          -  History of laser treatment for rosacea within 6 weeks prior to visit 1

          -  Alcoholic or drug abuse patients

          -  Patients who are treated with prohibited concomitant drugs or considered to
             inevitably require treatment with prohibited concomitant drugs during the study
             period

          -  Renal function impairment with creatinine level higher than twice of maximum normal
             range

          -  Hepatic function impairment with AST/ALT higher than twice of maximum normal range

          -  Pregnant and lactating woman, woman with child-birth potential(should have negative
             pregnancy test at the baseline visit of the study)

          -  Participation in another clinical study within 1 month prior to screening

          -  Patients considered ineligible for study participation by the principal investigator
             or sub-investigator for other reasons; rosacea due to other medical (liver disease,
             renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BeomJoon Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Chungang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
